Market closedNon-fractional

Inozyme Pharma/INZY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Inozyme Pharma

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

Ticker

INZY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

59

Inozyme Pharma Metrics

BasicAdvanced
$278M
Market cap
-
P/E ratio
-$1.37
EPS
1.54
Beta
-
Dividend rate
$278M
1.54
14.052
13.393
38.457
39.243
-18.85%
-32.56%
-69.41%
2.33
2.33
-3.261
-13.39%
-27.56%

What the Analysts think about Inozyme Pharma

Analyst Ratings

Majority rating from 8 analysts.
Buy

Inozyme Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$23M
8.37%
Profit margin
0.00%
NaN%

Inozyme Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.56%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.29
-$0.33
-$0.38
-
Expected
-$0.43
-$0.32
-$0.32
-$0.36
-$0.39
Surprise
-19.17%
-8.31%
3.59%
5.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Inozyme Pharma stock?

Inozyme Pharma (INZY) has a market cap of $278M as of July 06, 2024.

What is the P/E ratio for Inozyme Pharma stock?

The price to earnings (P/E) ratio for Inozyme Pharma (INZY) stock is 0 as of July 06, 2024.

Does Inozyme Pharma stock pay dividends?

No, Inozyme Pharma (INZY) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Inozyme Pharma dividend payment date?

Inozyme Pharma (INZY) stock does not pay dividends to its shareholders.

What is the beta indicator for Inozyme Pharma?

Inozyme Pharma (INZY) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Inozyme Pharma stock

Buy or sell Inozyme Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing